Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...
Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...
Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $132 a share in cash for a total equity value of about $14.6 ...
About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited. If the FDA approves the twice-daily pill on Thursday ...
US regulators have approved the first pill that can be digitally tracked through the body. The Abilify MyCite aripiprazole tablets - for treating schizophrenia and manic episodes - have an ...
Schizophrenia is a serious mental illness that ... If you have a hard time remembering whether or not you took a medicine, use a pill holder that will organize your meds by time of day.
Intra-Cellular Therapies Inc. makes Caplyta, a once-daily pill for treating adults with schizophrenia and depression tied to bipolar disorder. The drug brought in $175 million in last year’s ...